Literature DB >> 19423455

Low molecular weight heparin in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study.

Xin-Sheng Lu1, Fu Qiu, Jie-Qin Li, Qin-Qiao Fan, Ri-Guang Zhou, Yu-Hang Ai, Kai-Cheng Zhang, Yi-Xiong Li.   

Abstract

OBJECTIVE: To study the effect of low molecular weight heparin (LMWH) in the treatment of severe acute pancreatitis (SAP).
METHODS: A total of 265 SAP patients were randomly divided into two groups: firstly, the conventional treatment group (C group, n = 130; and secondly the conventional treatment plus the LMWH treatment group (LT group, n = 135). The clinical parameters, laboratory parameters and computed tomography (CT) score of pancreatic necrosis (CTSPN) in the two groups were compared.
RESULTS: On admission, all the clinical parameters, laboratory parameters and CTSPN in the two groups were not significantly different (p > 0.05). However, after treatment, in LT group, the clinical presentation improvement rate and laboratory parameters improvement were significantly higher than those in C group (p < 0.05-0.01), and the acute physiology and chronic health evaluation (APACHE) II score, complication rate, mortality and mean hospital stay in LT group were obviously lower than those in C group (p < 0.05-0.01). The CT score in LT group was much lower than that in C group (p < 0.05). Two weeks after treatment FBI decreased obviously in C group, but not in LT group, and no haemorrhagic complications occurred.
CONCLUSIONS: LMWH can enhance the effect of conventional treatment for SAP, and can markedly decrease the mortality of SAP. LMWH is a simple, safe, economic and effective method for treatment of SAP. It is can be used in every hospital.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423455     DOI: 10.1016/s1015-9584(09)60017-8

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  6 in total

1.  Protective effect of low-molecular-weight heparin on pancreatic encephalopathy in severe acute pancreatic rats.

Authors:  Fu Qiu; Xin-sheng Lu; Yu-kun Huang
Journal:  Inflamm Res       Date:  2012-07-18       Impact factor: 4.575

Review 2.  The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications.

Authors:  Paulina Dumnicka; Dawid Maduzia; Piotr Ceranowicz; Rafał Olszanecki; Ryszard Drożdż; Beata Kuśnierz-Cabala
Journal:  Int J Mol Sci       Date:  2017-02-08       Impact factor: 5.923

3.  Pretreatment with Warfarin Attenuates the Development of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats.

Authors:  Dawid Maduzia; Piotr Ceranowicz; Jakub Cieszkowski; Krystyna Gałązka; Beata Kuśnierz-Cabala; Zygmunt Warzecha
Journal:  Molecules       Date:  2020-05-27       Impact factor: 4.411

Review 4.  New Applications of Heparin and Other Glycosaminoglycans.

Authors:  Marcelo Lima; Timothy Rudd; Edwin Yates
Journal:  Molecules       Date:  2017-05-06       Impact factor: 4.411

5.  Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis.

Authors:  Jun-Dong DU; Xi Zheng; Zhi-Qiang Huang; Shou-Wang Cai; Jing-Wang Tan; Zhan-Liang Li; Yong-Ming Yao; Hua-Bo Jiao; Hui-Nan Yin; Zi-Man Zhu
Journal:  Exp Ther Med       Date:  2014-04-25       Impact factor: 2.447

Review 6.  Consequences of COVID-19 for the Pancreas.

Authors:  Urszula Abramczyk; Maciej Nowaczyński; Adam Słomczyński; Piotr Wojnicz; Piotr Zatyka; Aleksandra Kuzan
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.